Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study

Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study

Background: Dual blockade therapy encorafenib–cetuximab (EC) was recently established as the standard of care for second- or third-line treatment for BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients based on BEACON phase III study results. The CONFIDENCE study aims to provide insight a...

Full description

Saved in:
Bibliographic Details
Main Authors: A. Fernández-Montes, J. Ros, P. García-Alfonso, B. Graña, E. Brozos-Vázquez, M. Melián, A.Mª Jiménez-Gordo, E. Martínez de Castro, I. Busquier, A. Ferrández Arias, C. Grávalos, M. Covela, A. Ruíz-Casado, E. González-Flores, Mª J. Safont, J.Mª Cano, C. Alonso-López, Mª J. Gómez-Reina, O. Donnay, J.L. Manzano-Mozo, P. Sampedro Domarco, E. Falcó, N. Rodríguez, C. García-Benito, E. Aranda
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:ESMO Real World Data and Digital Oncology
Subjects:
BRAFV600E-mutated metastatic colorectal cancer
cetuximab
encorafenib
real-world data
survival
safety
Online Access:http://www.sciencedirect.com/science/article/pii/S294982012400033X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S294982012400033X

Similar Items